A Phase 1 Safety Study of Dengusiil in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 17, 2019

Primary Completion Date

June 11, 2021

Study Completion Date

June 11, 2021

Conditions
Prevention of Dengue Fever
Interventions
BIOLOGICAL

Dengusiil

Dengusiil is provided as lyophilized powder to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted vaccine is injected as a single 0.5 mL subcutaneous (SC) dose.

BIOLOGICAL

Placebo

Placebo is supplied as a vial of lyophilized powder containing all the components of the vaccine except dengue virus serotypes (DENV1, 2, 3 and 4) to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted product is injected as a single 0.5 mL subcutaneous (SC) dose.

Trial Locations (1)

5000

CMAX Clinical Research Pty Ltd, Adelaide

All Listed Sponsors
collaborator

PPD Australia Pty Ltd

UNKNOWN

lead

Serum Institute of India Pvt. Ltd.

INDUSTRY

NCT04035278 - A Phase 1 Safety Study of Dengusiil in Healthy Adults | Biotech Hunter | Biotech Hunter